腹主动脉瘤腔内隔绝术中期单中心结果:支架移植物移位、继发破裂和器械相关再干预率高
这项回顾性观察研究纳入2013年3月至2018年1月间接受腔内动脉瘤隔绝术(EVAS)治疗的腹主动脉疾病患者70例,中位临床随访50.5个月。尽管技术成功率达97.1%,中期结果令人失望:5例继发腹主动脉瘤破裂(7.1%),25例(35.7%)接受再干预,5年免于支架移植物移位率仅47.3%。
要点
- EVAS中期再干预率高达35.7%,主要原因为血栓并发症、支架移植物移位和I型内漏。
- 5年免于支架移植物移位率仅47.3%,需密切影像随访警惕移位及继发破裂。
- 超出原版使用说明(IFU)治疗者I型内漏发生率显著更高(P = .012)。
核心结论
- EVAS技术和初期结果满意,但中期结果令人失望。
- 强烈建议对所有EVAS治疗后患者执行密切随访方案,尤其警惕支架移植物移位以预防继发I型内漏和破裂。
研究设计与样本
- 回顾性观察研究,纳入2013年3月至2018年1月间因腹主动脉瘤或腹部穿透性主动脉溃疡接受EVAS治疗的全部患者70例(67例男性;中位年龄72.5岁)。
- 比较IFU组与非IFU组在生存率、免于再干预生存率、免于I型内漏率和免于支架移植物移位率方面的差异。
主要发现
- 技术成功68例(97.1%);中位临床随访50.5个月(四分位距29.3-62.7个月),中位CT血管造影随访38.5个月(四分位距17.1-60.2个月)。
- 研究期间死亡5例(7.1%),其中4例(5.7%)为动脉瘤相关死亡;检出5例继发腹主动脉瘤破裂(7.1%)。
- 25/70例(35.7%)接受35次再干预,主要原因为血栓并发症(18.6%)、支架移植物移位(17.1%)和I型内漏(12.9%)。
- 全队列30天、1年、3年和5年估计免于再干预生存率分别为94.3%、88.5%、72%和56.9%;1年、3年和5年免于支架移植物移位率分别为98.6%、82.0%和47.3%。
关键数值与推荐
- IFU组30天、1年、3年和5年估计免于I型内漏率分别为100%、100%、94.9%和91.1%,与非IFU组的79.5%、72.2%、72.2%和72.2%相比差异有统计学意义(P = .012)。
临床怎么用
- EVAS术后应执行密切随访方案,重点监测支架移植物移位,以预防继发I型内漏和破裂。
- 对超出IFU治疗的患者应尤其警惕I型内漏风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report procedural results and mid-term follow-up outcomes of patients treated with endovascular aneurysm sealing (EVAS) for abdominal aortic disease. METHODS: In this retrospective observational study, all patients treated with EVAS between March 2013 and January 2018 for abdominal aortic aneurysm (AAA) or abdominal penetrating aortic ulcer were included. The datasets included demographics, aneurysm morphology, and procedural and clinical surveillance outcomes. Furthermore, patients treated within the original instructions for use (IFU-group) were compared with patients treated outside the IFU (non-IFU-group) with regard to survival, reintervention-free survival, freedom from type I endoleak, and freedom from stent graft migration. RESULTS: Seventy patients were included (67 male; median age, 72.5 years). Sixty-five patients were treated for AAA and 5 patients for abdominal penetrating aortic ulcer. Sixty-nine cases were treated electively (98.6%). Technical success was achieved in 68 cases (97.1%). The median clinical follow-up was 50.5 months (interquartile range, 29.3-62.7 months) with a median computed tomography angiographic follow-up of 38.5 months (interquartile range, 17.1-60.2 months). There were five deaths during the study period (7.1%), four of which were aneurysm related (5.7%). Five secondary AAA ruptures were detected (7.1%). Overall, 25 of 70 patients (35.7%) underwent 35 reinterventions, mostly owing to thrombotic complications (18.6%), stent graft migration (17.1%), and type I endoleak (12.9%). Fifteen patients were treated outside of the IFU (non-IFU-group) (21.4%). The estimated reintervention-free survival for the entire cohort at 30 days and 1, 3, and 5 years was 94.3%, 88.5%, 72%, and 56.9%, respectively. Freedom from stent graft migration at 1, 3, and 5 years was 98.6%, 82.0%, and 47.3%, respectively. The estimated freedom from type I endoleak at 30 days and 1, 3, and 5 years in the IFU-group was 100%, 100%, 94.9% and, 91.1% and significantly different when compared with the non-IFU-group with 79.5%, 72.2%, 72.2%, and 72.2% (P = .012). CONCLUSIONS: Although the technical and initial results were satisfying, the mid-term results were disappointing. The enforcement of a close follow-up protocol for all patients treated with EVAS, especially vigilant for stent graft migration to prevent secondary type I endoleak and rupture, is strongly recommended.
引用
- Hatzl J, Peters AS, Pfeiffer S, et al. Midterm single-center results after endovascular aneurysm sealing reveal a high rate of stent graft migration, secondary aneurysm ruptures, and device-related reinterventions. J Vasc Surg. 2021. PMID: 33639234. doi:10.1016/j.jvs.2021.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。